News
RNAC
0.7293
-2.76%
-0.0207
Weekly Report: what happened at RNAC last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at RNAC last week (0212-0216)?
Weekly Report · 02/19 11:00
Weekly Report: what happened at RNAC last week (0205-0209)?
Weekly Report · 02/12 10:51
Weekly Report: what happened at RNAC last week (0129-0202)?
Weekly Report · 02/05 10:58
Weekly Report: what happened at RNAC last week (0122-0126)?
Weekly Report · 01/29 10:49
Cartesian: [Amend]Current report
Press release · 01/23 22:39
SolarEdge Layoffs 2024: What to Know About the Latest SEDG Job Cuts
SolarEdge (SEDG) stock is up 5.8% as of Monday morning. The solar energy company is laying off 900 of its employees. SolarEdge is one of several companies to announce layoffs in the first month of the year. Nio (NIO), Cartesian Therapeutics (RNAC) and B. Riley Financial (RILY) also made news on Monday.
Investorplace · 01/22 14:48
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
Cartyesian Therapeutics (NASDAQ:RNAC) stock is falling on Monday after the company revealed a delisting notice. The price of RNAC stock has been trading below the $1 minimum bid required to remain on the Nasdaq Exchange for 30 consecutive days. The company has 180 days to get the price ofRNAC stock back above the minimum bid. RNAC shares are down 5% as of Monday morning.
Investorplace · 01/22 14:19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
MSP Recovery (NASDAQ:LIFW) stock is rocketing more than 30% despite insider selling of the shares. The biggest pre-market stock movers on Monday are insider selling, special meetings, a delisting notice and more. B. Riley Financial stock is plummeting close to 18% on Monday.
Investorplace · 01/22 12:42
Weekly Report: what happened at RNAC last week (0115-0119)?
Weekly Report · 01/22 10:53
Cartesian: Current report
Press release · 01/19 22:24
Weekly Report: what happened at RNAC last week (0108-0112)?
Weekly Report · 01/15 10:50
Cartesian: Securities to be offered to employees in employee benefit plans
Press release · 01/12 23:24
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 6.7% to $0.26 during Wednesday's after-market session. Semler Scientific shares rose 5.99% and China Pharma Holding (AMEX:CPHI) stock rose by 5.82%. Losers 180 Life Sciences (NASdaq:ATNF) shares fell 18.2% and Alpha Tau Medical stock fell 7.28%.
Benzinga · 01/10 21:31
Cartesian: Current report
Press release · 01/08 16:26
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Benzinga · 01/08 12:25
Cartesian Therapeutics Announces Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis. Cartesian's lead mRNA cell therapy candidate is a potential first-in-class CAR T-cell therapy for autoimmune diseases.
Benzinga · 01/08 12:25
Weekly Report: what happened at RNAC last week (0101-0105)?
Weekly Report · 01/08 10:53
Cartesian: Statement of changes in beneficial ownership of securities
Press release · 01/05 00:39
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.